Old drugs, novel ways out: Drug resistance toward cytotoxic chemotherapeutics

Drug Resistance Updates

Volumn 28, Issue , 2016, Pages 65-81

  Wijdeven, Ruud H ^a,b   Pang, Baoxu ^c   Assaraf, Yehuda G ^d   Neefjes, Jacques ^a,b  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Anticancer drugs; Biomarkers; Cancer; Chemotherapeutics; Cisplatin; Doxorubicin (adriamycin); Drug resistance

Indexed keywords

ALKYLATING AGENT; ANTIMETABOLITE; ANTIMITOTIC AGENT; ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; DEOXYURIDINE TRIPHOSPHATE PYROPHOSPHATASE; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; GYRASE INHIBITOR; IFOSFAMIDE; METHOTREXATE; MICROTUBULE ASSOCIATED PROTEIN; NAVELBINE; PACLITAXEL; PEMETREXED; TOPOTECAN; TUMOR MARKER; TUMOR PROTEIN;

APOPTOSIS; ARTICLE; CANCER PATIENT; CANCER RESISTANCE; CHEMOSENSITIVITY; CYTOTOXICITY; DNA REPAIR; DNA REPLICATION; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; HUMAN; NONHUMAN; PERSONALIZED MEDICINE; POLYPHARMACY; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR IMMUNOLOGY; TUMOR MICROENVIRONMENT; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; MULTIDRUG RESISTANCE; NEOPLASM; PATHOLOGY; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BIOMARKERS, TUMOR; CISPLATIN; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM PROTEINS; NEOPLASMS; PRECISION MEDICINE; SIGNAL TRANSDUCTION;

EID: 84980367693     PISSN: 13687646     EISSN: 15322084     Source Type: Journal    
DOI: 10.1016/j.drup.2016.07.001     Document Type: Article

References (219)

1. Adar, Y., Stark, M., Bram, E.E., Nowak-Sliwinska, P., van den Bergh, H., Szewczyk, G., Sarna, T., Skladanowski, A., Griffioen, A.W., Assaraf, Y.G., Imidazoacridinone-dependent lysosomal photodestruction: a pharmacological Trojan horse approach to eradicate multidrug-resistant cancers. Cell Death Dis., 3, 2012, pe293.
2. Albini, A., Sporn, M.B., The tumour microenvironment as a target for chemoprevention. Nat. Rev. Cancer 7 (2007), 139–147.
3. Alkema, N.G., Wisman, G.B., van der Zee, A.G., van Vugt, M.A., de Jong, S., Studying platinum sensitivity and resistance in high-grade serous ovarian cancer: different models for different questions. Drug Resist. Updates: Rev. Comment. Antimicrob. Anticancer Chemother. 24 (2016), 55–69.
4. Alli, E., Bash-Babula, J., Yang, J.M., Hait, W.N., Effect of stathmin on the sensitivity to antimicrotubule drugs in human breast cancer. Cancer Res. 62:23 (2002), 6864–6869.
5. Anand, S., Penrhyn-Lowe, S., Venkitaraman, A.R., AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol. Cancer Cell 3:1 (2003), 51–62.
6. Assaraf, Y.G., Molecular basis of antifolate resistance. Cancer Metast. Rev. 26 (2007), 153–181.
7. Assaraf, Y.G., The role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis. Drug Resist. Updates: Rev. Comment. Antimicrob. Anticancer Chemother. 9 (2006), 227–246.
8. Assaraf, Y.G., Goldman, I.D., Loss of folic acid exporter function with markedly augmented folate accumulation in lipophilic antifolate-resistant mammalian cells. J. Biol. Chem. 272 (1997), 17460–17466.
9. Bai, W., Wu, Y., Zhang, P., Xi, Y., Correlations between expression levels of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase, and efficacy of 5-fluorouracil-based chemotherapy for advanced colorectal cancer. Int. J. Clin. Exp. Pathol. 8 (2015), 12333–12345.
10. Bandyopadhyay, K., Gjerset, R.A., Protein kinase CK2 is a central regulator of topoisomerase I hyperphosphorylation and camptothecin sensitivity in cancer cell lines. Biochemistry 50:5 (2011), 704–714.
11. Bandyopadhyay, K., Li, P., Gjerset, R.A., CK2-mediated hyperphosphorylation of topoisomerase I targets serine 506, enhances topoisomerase I-DNA binding, and increases cellular camptothecin sensitivity. PLoS One, 7(11), 2012, e50427.
12. Berger, J.M., Gamblin, S.J., Harrison, S.C., Wang, J.C., Structure and mechanism of DNA topoisomerase II. Nature 379:6562 (1996), 225–232.
13. Binenbaum, Y., Na'ara, S., Gil, Z., Gemcitabine resistance in pancreatic ductal adenocarcinoma. Drug Resist. Updates: Rev. Comment. Antimicrob. Anticancer Chemother. 23 (2015), 55–68.
14. Bonneau, C., Gurard-Levin, Z.A., Andre, F., Pusztai, L., Rouzier, R., Predictive and prognostic value of the tauprotein in breast cancer. Anticancer Res. 35:10 (2015), 5179–5184.
15. Borst, P., Evers, R., Kool, M., Wijnholds, J., A family of drug transporters: the multidrug resistance-associated proteins. J. Natl. Cancer Inst. 92:16 (2000), 1295–1302.
16. Bouchalova, K., Kharaishvili, G., Bouchal, J., Vrbkova, J., Megova, M., Hlobilkova, A., Triple negative breast cancer – BCL2 in prognosis and prediction. Curr. Drug Targets 15 (2014), 1166–1175 (Review).
17. Bowden, N.A., Nucleotide excision repair: why is it not used to predict response to platinum-based chemotherapy?. Cancer Lett. 346 (2014), 163–171.
18. Bulgar, A.D., Weeks, L.D., Miao, Y., Yang, S., Xu, Y., Guo, C., Markowitz, S., Oleinick, N., Gerson, S.L., Liu, L., Removal of uracil by uracil DNA glycosylase limits pemetrexed cytotoxicity: overriding the limit with methoxyamine to inhibit base excision repair. Cell Death Dis., 3, 2012, pe252.
19. Burgess, D.J., Doles, J., Zender, L., Xue, W., Ma, B., McCombie, W.R., Hannon, G.J., Lowe, S.W., Hemann, M.T., Topoisomerase levels determine chemotherapy response in vitro and in vivo. Proc. Natl. Acad. Sci. U. S. A. 105 (2008), 9053–9058.
20. Callaghan, R., Luk, F., Bebawy, M., Inhibition of the multidrug resistance P-glycoprotein: time for a change of strategy?. Drug Metab. Dispos.: Biol. Fate Chem. 42 (2014), 623–631.
21. Cao, H., Phan, H., Yang, L.X., Improved chemotherapy for hepatocellular carcinoma. Anticancer Res. 32 (2012), 1379–1386.
22. Carmena, M., Wheelock, M., Funabiki, H., Earnshaw, W.C., The chromosomal passenger complex (CPC): from easy rider to the godfather of mitosis. Nat Rev Mol Cell Biol 13:12 (2012), 789–803.
23. Cayre, A., Penault-Llorca, F., De Latour, M., Rolhion, C., Feillel, V., Ferriere, J.P., Kwiatkowski, F., Finat-Duclos, F., Verrelle, P., O(6)-methylguanine-DNA methyl transferase gene expression and prognosis in breast carcinoma. Int. J. Oncol. 21 (2002), 1125–1131.
24. Ceccaldi, R., O'Connor, K.W., Mouw, K.W., Li, A.Y., Matulonis, U.A., D'Andrea, A.D., Konstantinopoulos, P.A., A unique subset of epithelial ovarian cancers with platinum sensitivity and PARP inhibitor resistance. Cancer Res. 75 (2015), 628–634.
25. Chapman, J.R., Taylor, M.R., Boulton, S.J., Playing the end game: DNA double-strand break repair pathway choice. Mol. Cell 47 (2012), 497–510.
26. Chattopadhyay, S., Tamari, R., Min, S.H., Zhao, R., Tsai, E., Goldman, I.D., Commentary: a case for minimizing folate supplementation in clinical regimens with pemetrexed based on the marked sensitivity of the drug to folate availability. Oncologist 12 (2007), 808–815.
27. ClinicalTrial, S.N.U.H., Adjuvant Gemcitabine Versus 5-FU/Leucovorin Based on hENT1 Immunostaining. 2015 ClinicalTrials.gov [Internet], NCT02486497.
28. Coon, J.S., Marcus, E., Gupta-Burt, S., Seelig, S., Jacobson, K., Chen, S., Renta, V., Fronda, G., Preisler, H.D., Amplification and overexpression of topoisomerase IIα predict response to anthracycline-based therapy in locally advanced breast cancer. Clin. Cancer Res. 8 (2002), 1061–1067.
29. Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., Chau, I., Van Cutsem, E., Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 351 (2004), 337–345.
30. Czabotar, P.E., Lessene, G., Strasser, A., Adams, J.M., Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat. Rev. Mol. Cell Biol. 15 (2014), 49–63.
31. De Donato, M., Mariani, M., Petrella, L., Martinelli, E., Zannoni, G.F., Vellone, V., Ferrandina, G., Shahabi, S., Scambia, G., Ferlini, C., Class III beta-tubulin and the cytoskeletal gateway for drug resistance in ovarian cancer. J. Cell. Physiol. 227 (2012), 1034–1041.
32. Dear, R.F., McGeechan, K., Jenkins, M.C., Barratt, A., Tattersall, M.H., Wilcken, N., Combination versus sequential single agent chemotherapy for metastatic breast cancer. Cochr. Database Syst. Rev., 12, 2013, pCd008792.
33. Delaney, C.A., Wang, L.Z., Kyle, S., White, A.W., Calvert, A.H., Curtin, N.J., Durkacz, B.W., Hostomsky, Z., Newell, D.R., Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines. Clin. Cancer res.: off. J. Am. Assoc. Cancer Res. 6 (2000), 2860–2867.
34. Ditchfield, C., Johnson, V.L., Tighe, A., Ellston, R., Haworth, C., Johnson, T., …, Taylor, S.S., Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores. J. Cell Biol. 161:2 (2003), 267–280.
35. Drori, S., Jansen, G., Mauritz, R., Peters, G.J., Assaraf, Y.G., Clustering of mutations in the first transmembrane domain of the human reduced folate carrier in GW1843U89-resistant leukemia cells with impaired antifolate transport and augmented folate uptake. J. Biol. Chem. 275 (2000), 30855–30863.
36. Dumontet, C., Jordan, M.A., Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat. Rev. Drug Discov. 9:10 (2010), 790–803.
37. Edwards, S.L., Brough, R., Lord, C.J., Natrajan, R., Vatcheva, R., Levine, D.A., Boyd, J., Reis-Filho, J.S., Ashworth, A., Resistance to therapy caused by intragenic deletion in BRCA2. Nature 451 (2008), 1111–1115.
38. Elmore, S., Apoptosis: a review of programmed cell death. Toxicol. Pathol. 35 (2007), 495–516.
39. Emadi, A., Jones, R.J., Brodsky, R.A., Cyclophosphamide and cancer: golden anniversary. Nat. Rev. Clin. Oncol. 6 (2009), 638–647.
40. Farmer, H., McCabe, N., Lord, C.J., Tutt, A.N., Johnson, D.A., Richardson, T.B., Santarosa, M., Dillon, K.J., Hickson, I., Knights, C., Martin, N.M., Jackson, S.P., Smith, G.C., Ashworth, A., Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434 (2005), 917–921.
41. Ferreira, J.A., Peixoto, A., Neves, M., Gaiteiro, C., Reis, C.A., Assaraf, Y.G., Santos, L.L., Mechanisms of cisplatin resistance and targeting of cancer stem cells: adding glycosylation to the equation. Drug Resist. Updates: Rev. Comment. Antimicrob. Anticancer Chemother. 24 (2016), 34–54.
42. Fink, D., Nebel, S., Aebi, S., Zheng, H., Cenni, B., Nehme, A., Christen, R.D., Howell, S.B., The role of DNA mismatch repair in platinum drug resistance. Cancer Res. 56 (1996), 4881–4886.
43. Fischer, K.R., Durrans, A., Lee, S., Sheng, J., Li, F., Wong, S.T., Choi, H., El Rayes, T., Ryu, S., Troeger, J., Schwabe, R.F., Vahdat, L.T., Altorki, N.K., Mittal, V., Gao, D., Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature 527 (2015), 472–476.
44. Formentini, A., Henne-Bruns, D., Kornmann, M., Thymidylate synthase expression and prognosis of patients with gastrointestinal cancers receiving adjuvant chemotherapy: a review. Langenbeck's Arch. Surg./Deutsche Gesellschaft Chirurgie 389 (2004), 405–413.
45. Fujita, H., Ohuchida, K., Mizumoto, K., Itaba, S., Ito, T., Nakata, K., Yu, J., Kayashima, T., Souzaki, R., Tajiri, T., Manabe, T., Ohtsuka, T., Tanaka, M., Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy. Neoplasia (New York, NY) 12 (2010), 807–817.
46. Furlong, F., Fitzpatrick, P., O'Toole, S., Phelan, S., McGrogan, B., Maguire, A., …, McCann, A., Low MAD2 expression levels associate with reduced progression-free survival in patients with high-grade serous epithelial ovarian cancer. J. Pathol. 226:5 (2012), 746–755.
47. Galluzzi, L., Senovilla, L., Vitale, I., Michels, J., Martins, I., Kepp, O., Castedo, M., Kroemer, G., Molecular mechanisms of cisplatin resistance. Oncogene 31 (2012), 1869–1883.
48. Galluzzi, L., Vitale, I., Michels, J., Brenner, C., Szabadkai, G., Harel-Bellan, A., Castedo, M., Kroemer, G., Systems biology of cisplatin resistance: past, present and future. Cell Death Dis., 5, 2014, pe1257.
49. Ganguly, A., Yang, H., Cabral, F., Overexpression of mitotic centromere-associated Kinesin stimulates microtubule detachment and confers resistance to paclitaxel. Mol. Cancer Ther. 10:6 (2011), 929–937.
50. Gao, J., Zheng, Z., Rawal, B., Schell, M.J., Bepler, G., Haura, E.B., Mirk/Dyrk1B, a novel therapeutic target, mediates cell survival in non-small cell lung cancer cells. Cancer Biol. Ther. 8 (2009), 1671–1679.
51. Gao, J., Aksoy, B.A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S.O., …, Schultz, N., Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal, 6(269), 2013, pl1.
52. Gatti, L., Cassinelli, G., Zaffaroni, N., Lanzi, C., Perego, P., New mechanisms for old drugs: Insights into DNA-unrelated effects of platinum compounds and drug resistance determinants. Drug Resist. Updates: Rev. Comment. Antimicrob. Anticancer Chemother. 20 (2015), 1–11.
53. Giannakakou, P., Sackett, D.L., Kang, Y.K., Zhan, Z., Buters, J.T., Fojo, T., Poruchynsky, M.S., Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. J. Biol. Chem. 272:27 (1997), 17118–17125.
54. Gianni, L., Herman, E.H., Lipshultz, S.E., Minotti, G., Sarvazyan, N., Sawyer, D.B., Anthracycline cardiotoxicity: from bench to bedside. J. Clin. Oncol. 26 (2008), 3777–3784.
55. Giovannetti, E., Del Tacca, M., Mey, V., Funel, N., Nannizzi, S., Ricci, S., Orlandini, C., Boggi, U., Campani, D., Del Chiaro, M., Iannopollo, M., Bevilacqua, G., Mosca, F., Danesi, R., Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Res. 66 (2006), 3928–3935.
56. Gonen, N., Assaraf, Y.G., Antifolates in cancer therapy: structure, activity and mechanisms of drug resistance. Drug Resist. Updates: Rev. Comment. Antimicrob. Anticancer Chemother. 15 (2012), 183–210.
57. Gorlick, R., Goker, E., Trippett, T., Steinherz, P., Elisseyeff, Y., Mazumdar, M., Flintoff, W.F., Bertino, J.R., Defective transport is a common mechanism of acquired methotrexate resistance in acute lymphocytic leukemia and is associated with decreased reduced folate carrier expression. Blood 89 (1997), 1013–1018.
58. Gottesman, M.M., Fojo, T., Bates, S.E., Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer 2 (2002), 48–58.
59. Greenhalf, W., Ghaneh, P., Neoptolemos, J.P., Palmer, D.H., Cox, T.F., Lamb, R.F., Garner, E., Campbell, F., Mackey, J.R., Costello, E., Moore, M.J., Valle, J.W., McDonald, A.C., Carter, R., Tebbutt, N.C., Goldstein, D., Shannon, J., Dervenis, C., Glimelius, B., Deakin, M., Charnley, R.M., Lacaine, F., Scarfe, A.G., Middleton, M.R., Anthoney, A., Halloran, C.M., Mayerle, J., Olah, A., Jackson, R., Rawcliffe, C.L., Scarpa, A., Bassi, C., Buchler, M.W., Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial. J. Natl. Cancer Inst., 106, 2014, pdjt347.
60. Guo, W., Healey, J.H., Meyers, P.A., Ladanyi, M., Huvos, A.G., Bertino, J.R., Gorlick, R., Mechanisms of methotrexate resistance in osteosarcoma. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 5 (1999), 621–627.
61. Hanahan, D., Weinberg, R.A., Hallmarks of cancer: the next generation. Cell 144 (2011), 646–674.
62. Hande, K.R., Clinical applications of anticancer drugs targeted to topoisomerase II. Biochim. Biophys. Acta (BBA) – Gene Struct. Expr. 1400 (1998), 173–184.
63. Hari, M., Loganzo, F., Annable, T., Tan, X., Musto, S., Morilla, D.B., …, Greenberger, L.M., Paclitaxel-resistant cells have a mutation in the paclitaxel-binding region of beta-tubulin (Asp26Glu) and less stable microtubules. Mol. Cancer Ther. 5:2 (2006), 270–278.
64. Hazar-Rethinam, M., de Long, L.M., Gannon, O.M., Boros, S., Vargas, A.C., Dzienis, M., Mukhopadhyay, P., Saenz-Ponce, N., Dantzic, D.D., Simpson, F., Saunders, N.A., RacGAP1 is a novel downstream effector of E2F7-dependent resistance to doxorubicin and is prognostic for overall survival in squamous cell carcinoma. Mol. Cancer Therapeut. 14 (2015), 1939–1950.
65. Hazar-Rethinam, M., de Long, L.M., Gannon, O.M., Topkas, E., Boros, S., Vargas, A.C., Dzienis, M., Mukhopadhyay, P., Simpson, F., Endo-Munoz, L., Saunders, N.A., A novel E2F/sphingosine kinase 1 axis regulates anthracycline response in squamous cell carcinoma. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 21 (2015), 417–427.
66. Herlevsen, M., Oxford, G., Owens, C.R., Conaway, M., Theodorescu, D., Depletion of major vault protein increases doxorubicin sensitivity and nuclear accumulation and disrupts its sequestration in lysosomes. Mol. Cancer Therapeut. 6 (2007), 1804–1813.
67. Hofree, M., Shen, J.P., Carter, H., Gross, A., Ideker, T., Network-based stratification of tumor mutations. Nat. Methods 10 (2013), 1108–1115.
68. Holm, C., Covey, J.M., Kerrigan, D., Pommier, Y., Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells. Cancer Res. 49:22 (1989), 6365–6368.
69. Holohan, C., Van Schaeybroeck, S., Longley, D.B., Johnston, P.G., Cancer drug resistance: an evolving paradigm. Nat. Rev. Cancer 13 (2013), 714–726.
70. Horisberger, K., Erben, P., Muessle, B., Woernle, C., Stroebel, P., Kaehler, G., …, Hofheinz, R.D., Topoisomerase I expression correlates to response to neoadjuvant irinotecan-based chemoradiation in rectal cancer. Anticancer Drugs 20:6 (2009), 519–524.
71. Horwitz, S.B., Horwitz, M.S., Effects of camptothecin on the breakage and repair of DNA during the cell cycle. Cancer Res. 33:11 (1973), 2834–2836.
72. Hsiang, Y.H., Hertzberg, R., Hecht, S., Liu, L.F., Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J. Biol. Chem. 260:27 (1985), 14873–14878.
73. Hsiang, Y.H., Lihou, M.G., Liu, L.F., Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res. 49:18 (1989), 5077–5082.
74. Huang, D., Zhou, Y., Nucleotide excision repair gene polymorphisms and prognosis of non-small cell lung cancer patients receiving platinum-based chemotherapy: a meta-analysis based on 44 studies. Biomed. Rep. 2 (2014), 452–462.
75. Huang, S., Holzel, M., Knijnenburg, T., Schlicker, A., Roepman, P., McDermott, U., Garnett, M., Grernrum, W., Sun, C., Prahallad, A., Groenendijk, F.H., Mittempergher, L., Nijkamp, W., Neefjes, J., Salazar, R., Ten Dijke, P., Uramoto, H., Tanaka, F., Beijersbergen, R.L., Wessels, L.F., Bernards, R., MED12 controls the response to multiple cancer drugs through regulation of TGF-beta receptor signaling. Cell 151 (2012), 937–950.
76. Huang, L.N., Wang, D.S., Chen, Y.Q., Zhao, C.L., Gong, B.L., Jiang, A.B., …, Hu, F.D., Expression of survivin and patients survival in non-small cell lung cancer: a meta-analysis of the published studies. Mol. Biol. Rep. 40:2 (2013), 917–924.
77. Hung, C.C., Chien, C.Y., Chiang, W.F., Lin, C.S., Hour, T.C., Chen, H.R., …, Chen, J.Y., p22phox confers resistance to cisplatin, by blocking its entry into the nucleus. Oncotarget 6:6 (2015), 4110–4125.
78. Igney, F.H., Krammer, P.H., Death and anti-death: tumour resistance to apoptosis. Nat. Rev. Cancer 2 (2002), 277–288.
79. Iida, N., Dzutsev, A., Stewart, C.A., Smith, L., Bouladoux, N., Weingarten, R.A., Molina, D.A., Salcedo, R., Back, T., Cramer, S., Dai, R.M., Kiu, H., Cardone, M., Naik, S., Patri, A.K., Wang, E., Marincola, F.M., Frank, K.M., Belkaid, Y., Trinchieri, G., Goldszmid, R.S., Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment,. Science (New York, NY) 342 (2013), 967–970.
80. Ikeguchi, M., Arai, Y., Maeta, Y., Ashida, K., Katano, K., Wakatsuki, T., Topoisomerase I expression in tumors as a biological marker for CPT-11 chemosensitivity in patients with colorectal cancer. Surg. Today 41:9 (2011), 1196–1199.
81. Ivy, K.D., Kaplan, J.H., A re-evaluation of the role of hCTR1, the human high-affinity copper transporter, in platinum-drug entry into human cells. Mol. Pharmacol. 83:6 (2013), 1237–1246.
82. Jabeen, S., Holmboe, L., Alnaes, G.I., Andersen, A.M., Hall, K.S., Kristensen, V.N., Impact of genetic variants of RFC1, DHFR and MTHFR in osteosarcoma patients treated with high-dose methotrexate. Pharmacogenom. J. 15 (2015), 385–390.
83. Jansen, G., Mauritz, R., Drori, S., Sprecher, H., Kathmann, I., Bunni, M., Priest, D.G., Noordhuis, P., Schornagel, J.H., Pinedo, H.M., Peters, G.J., Assaraf, Y.G., A structurally altered human reduced folate carrier with increased folic acid transport mediates a novel mechanism of antifolate resistance. J. Biol. Chem. 273 (1998), 30189–30198.
84. Januchowski, R., Wojtowicz, K., Zabel, M., The role of aldehyde dehydrogenase (ALDH) in cancer drug resistance. Biomed. Pharmacother. = Biomed. Pharmacother. 67 (2013), 669–680.
85. Järvinen, T.A., Kononen, J., Pelto-Huikko, M., Isola, J., Expression of topoisomerase IIalpha is associated with rapid cell proliferation, aneuploidy, and c-erbB2 overexpression in breast cancer. Am. J. Pathol. 148 (1996), 2073–2082.
86. Jia, H., Cong, Q., Chua, J.F., Liu, H., Xia, X., Zhang, X., Lin, J., Habib, S.L., Ao, J., Zuo, Q., Fu, C., Li, B., p57Kip2 is an unrecognized DNA damage response effector molecule that functions in tumor suppression and chemoresistance. Oncogene 34 (2015), 3568–3581.
87. Jiang, Y.Z., Yu, K.D., Peng, W.T., Di, G.H., Wu, J., Liu, G.Y., Shao, Z.M., Enriched variations in TEKT4 and breast cancer resistance to paclitaxel. Nat. Commun., 5, 2014, 3802.
88. Jing, H., Kase, J., Dorr, J.R., Milanovic, M., Lenze, D., Grau, M., Beuster, G., Ji, S., Reimann, M., Lenz, P., Hummel, M., Dorken, B., Lenz, G., Scheidereit, C., Schmitt, C.A., Lee, S., Opposing roles of NF-kappaB in anti-cancer treatment outcome unveiled by cross-species investigations. Genes Dev. 25 (2011), 2137–2146.
89. Johnson, G.G., Lin, K., Cox, T.F., Oates, M., Sibson, D.R., Eccles, R., Lloyd, B., Gardiner, L.J., Carr, D.F., Pirmohamed, M., Strefford, J.C., Oscier, D.G., Gonzalez de Castro, D., Else, M., Catovsky, D., Pettitt, A.R., CYP2B6*6 is an independent determinant of inferior response to fludarabine plus cyclophosphamide in chronic lymphocytic leukemia. Blood 122 (2013), 4253–4258.
90. Kamal, N.S., Soria, J.C., Mendiboure, J., Planchard, D., Olaussen, K.A., Rousseau, V., Popper, H., Pirker, R., Bertrand, P., Dunant, A., Le Chevalier, T., Filipits, M., Fouret, P., MutS homologue 2 and the long-term benefit of adjuvant chemotherapy in lung cancer. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 16 (2010), 1206–1215.
91. Kanakkanthara, A., Teesdale-Spittle, P.H., Miller, J.H., Cytoskeletal alterations that confer resistance to anti-tubulin chemotherapeutics. Anticancer Agents Med. Chem. 13:1 (2013), 147–158.
92. Kang, Y., Hu, W., Ivan, C., Dalton, H.J., Miyake, T., Pecot, C.V., …, Sood, A.K., Role of focal adhesion kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancer. J. Natl. Cancer Inst. 105:19 (2013), 1485–1495.
93. Kar, S., Fan, J., Smith, M.J., Goedert, M., Amos, L.A., Repeat motifs of tau bind to the insides of microtubules in the absence of taxol. Embo. J. 22:1 (2003), 70–77.
94. Karki, R., Mariani, M., Andreoli, M., He, S., Scambia, G., Shahabi, S., Ferlini, C., betaIII-Tubulin: biomarker of taxane resistance or drug target?. Expert Opin. Therapeut. Targets 17 (2013), 461–472.
95. Kathawala, R.J., Gupta, P., Ashby, C.R. Jr., Chen, Z.S., The modulation of ABC transporter-mediated multidrug resistance in cancer: a review of the past decade. Drug Resist. Updates: Rev. Comment. Antimicrob. Anticancer Chemother. 18 (2015), 1–17.
96. Kavallaris, M., Microtubules and resistance to tubulin-binding agents. Nat. Rev. Cancer 10:3 (2010), 194–204.
97. Kawahara, A., Akagi, Y., Hattori, S., Mizobe, T., Shirouzu, K., Ono, M., Yanagawa, T., Kuwano, M., Kage, M., Higher expression of deoxyuridine triphosphatase (dUTPase) may predict the metastasis potential of colorectal cancer. J. Clin. Pathol. 62 (2009), 364–369.
98. Kelly, M.G., Alvero, A.B., Chen, R., Silasi, D.A., Abrahams, V.M., Chan, S., …, Mor, G., TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res. 66:7 (2006), 3859–3868.
99. Kim, H.K., Choi, I.J., Kim, C.G., Kim, H.S., Oshima, A., Michalowski, A., Green, J.E., A gene expression signature of acquired chemoresistance to cisplatin and fluorouracil combination chemotherapy in gastric cancer patients. PLoS ONE, 6, 2011, pe16694.
100. Kim, K.H., Roberts, C.W., Targeting EZH2 in cancer. Nat. Med. 22 (2016), 128–134.
101. Knuefermann, C., Lu, Y., Liu, B., Jin, W., Liang, K., Wu, L., …, Fan, Z., HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene. 22:21 (2003), 3205–3212.
102. Koehler, S.E., Ladner, R.D., Small interfering RNA-mediated suppression of dUTPase sensitizes cancer cell lines to thymidylate synthase inhibition. Mol. Pharmacol. 66 (2004), 620–626.
103. Koster, R., van Vugt, M.A., Timmer-Bosscha, H., Gietema, J.A., de Jong, S., Unravelling mechanisms of cisplatin sensitivity and resistance in testicular cancer. Expert Rev. Mol. Med., 15, 2013, pe12.
104. Kroemer, G., Galluzzi, L., Kepp, O., Zitvogel, L., Immunogenic cell death in cancer therapy. Annu. Rev. Immunol. 31 (2013), 51–72.
105. Kuang, X.Y., Chen, L., Zhang, Z.J., Liu, Y.R., Zheng, Y.Z., Ling, H., …, Shao, Z.M., Stathmin and phospho-stathmin protein signature is associated with survival outcomes of breast cancer patients. Oncotarget 6:26 (2015), 22227–22238.
106. Lai, D., Ho, K.C., Hao, Y., Yang, X., Taxol resistance in breast cancer cells is mediated by the hippo pathway component TAZ and its downstream transcriptional targets Cyr61 and CTGF. Cancer Res. 71:7 (2011), 2728–2738.
107. Leinonen, H.M., Kansanen, E., Polonen, P., Heinaniemi, M., Levonen, A.L., Role of the Keap1-Nrf2 pathway in cancer. Adv. Cancer Res. 122 (2014), 281–320.
108. Leong, C.O., Vidnovic, N., DeYoung, M.P., Sgroi, D., Ellisen, L.W., The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers. J. Clin. investig. 117 (2007), 1370–1380.
109. Li, Y., Ma, X., Wu, X., Liu, X., Liu, L., Prognostic significance of survivin in breast cancer: meta-analysis. Breast J. 20:5 (2014), 514–524.
110. Li, X., Yao, R., Yue, L., Qiu, W., Qi, W., Liu, S., …, Liang, J., FOXM1 mediates resistance to docetaxel in gastric cancer via up-regulating Stathmin. J. Cell Mol. Med. 18:5 (2014), 811–823.
111. Li, F., Sethi, G., Targeting transcription factor NF-kappaB to overcome chemoresistance and radioresistance in cancer therapy. Biochim. Biophys. Acta 1805 (2010), 167–180.
112. Liu, S.G., Gao, C., Zhang, R.D., Jiao, Y., Cui, L., Li, W.J., Chen, Z.P., Wu, M.Y., Zheng, H.Y., Zhao, X.X., Yue, Z.X., Li, Z.G., FPGS rs1544105 polymorphism is associated with treatment outcome in pediatric B-cell precursor acute lymphoblastic leukemia. Cancer Cell Int., 13, 2013, p107.
113. Livney, Y.D., Assaraf, Y.G., Rationally designed nanovehicles to overcome cancer chemoresistance. Adv. Drug Deliv. Rev. 65 (2013), 1716–1730.
114. Loi, S., Pommey, S., Haibe-Kains, B., Beavis, P.A., Darcy, P.K., Smyth, M.J., Stagg, J., CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), 11091–11096.
115. Mackey, J.R., Mani, R.S., Selner, M., Mowles, D., Young, J.D., Belt, J.A., Crawford, C.R., Cass, C.E., Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res. 58 (1998), 4349–4357.
116. Marechal, R., Mackey, J.R., Lai, R., Demetter, P., Peeters, M., Polus, M., Cass, C.E., Young, J., Salmon, I., Deviere, J., Van Laethem, J.L., Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 15 (2009), 2913–2919.
117. Mayer, I.A., Abramson, V.G., Lehmann, B.D., Pietenpol, J.A., New strategies for triple-negative breast cancer – deciphering the heterogeneity. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 20 (2014), 782–790.
118. Mazzanti, R., Gramantieri, L., Bolondi, L., Hepatocellular carcinoma: epidemiology and clinical aspects. Mol. Aspects Med. 29 (2008), 130–143.
119. McCarroll, J.A., Gan, P.P., Liu, M., Kavallaris, M., betaIII-tubulin is a multifunctional protein involved in drug sensitivity and tumorigenesis in non-small cell lung cancer. Cancer Res. 70 (2010), 4995–5003.
120. Meisenberg, C., Gilbert, D.C., Chalmers, A., Haley, V., Gollins, S., Ward, S.E., El-Khamisy, S.F., Clinical and cellular roles for TDP1 and TOP1 in modulating colorectal cancer response to irinotecan. Mol. Cancer Therapeut. 14 (2015), 575–585.
121. Minotti, G., Menna, P., Salvatorelli, E., Cairo, G., Gianni, L., Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev. 56 (2004), 185–229.
122. Miyashita, T., Reed, J.C., bcl-2 gene transfer increases relative resistance of S49.1 and WEHI7.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs. Cancer Res. 52 (1992), 5407–5411.
123. Miyoshi, Y., Kurosumi, M., Kurebayashi, J., Matsuura, N., Takahashi, M., Tokunaga, E., Egawa, C., Masuda, N., Kono, S., Morimoto, K., Kim, S.J., Okishiro, M., Yanagisawa, T., Ueda, S., Taguchi, T., Tamaki, Y., Noguchi, S., Predictive factors for anthracycline-based chemotherapy for human breast cancer. Breast Cancer (Tokyo Japan) 17 (2010), 103–109.
124. Mlak, R., Krawczyk, P., Ciesielka, M., Koziol, P., Homa, I., Powrozek, T., Prendecka, M., Milanowski, J., Malecka-Massalska, T., The relationship between RRM1 gene polymorphisms and effectiveness of gemcitabine-based first-line chemotherapy in advanced NSCLC patient. Clin. Transl. Oncol.: Off. Pub. Fed. Spanish Oncol. Soc. Natl. Cancer Inst. Mexico, 2015.
125. Mokady, D., Meiri, D., RhoGTPases – a novel link between cytoskeleton organization and cisplatin resistance. Drug Resist. Updates: Rev. Comment. Antimicrob. Anticancer Chemother. 19 (2015), 22–32.
126. Monteiro, L.J., Khongkow, P., Kongsema, M., Morris, J.R., Man, C., Weekes, D., Koo, C.Y., Gomes, A.R., Pinto, P.H., Varghese, V., Kenny, L.M., Charles Coombes, R., Freire, R., Medema, R.H., Lam, E.W., The Forkhead Box M1 protein regulates BRIP1 expression and DNA damage repair in epirubicin treatment. Oncogene 32 (2013), 4634–4645.
127. Morth, C., Valachis, A., Single-agent versus combination chemotherapy as first-line treatment for patients with advanced non-small cell lung cancer and performance status 2: a literature-based meta-analysis of randomized studies. Lung Cancer (Amst. Neth.) 84 (2014), 209–214.
128. Mu, Y., Lou, J., Srivastava, M., Zhao, B., Feng, X.H., Liu, T., Chen, J., Huang, J., SLFN11 Inhibits Checkpoint Maintenance and Homologous Recombination Repair. 2015, EMBO reports.
129. Ni Chonghaile, T., Sarosiek, K.A., Vo, T.T., Ryan, J.A., Tammareddi, A., Moore Vdel, G., Deng, J., Anderson, K.C., Richardson, P., Tai, Y.T., Mitsiades, C.S., Matulonis, U.A., Drapkin, R., Stone, R., Deangelo, D.J., McConkey, D.J., Sallan, S.E., Silverman, L., Hirsch, M.S., Carrasco, D.R., Letai, A., Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science (New York, NY) 334 (2011), 1129–1133.
130. Nitiss, J.L., Targeting DNA topoisomerase II in cancer chemotherapy. Nat. Rev. Cancer 9 (2009), 338–350.
131. Nobili, S., Napoli, C., Landini, I., Morganti, M., Cianchi, F., Valanzano, R., Tonelli, F., Cortesini, C., Mazzei, T., Mini, E., Identification of potential pharmacogenomic markers of clinical efficacy of 5-fluorouracil in colorectal cancer. Int. J. Cancer. J. Int. Cancer 128 (2011), 1935–1945.
132. Nordh, S., Ansari, D., Andersson, R., hENT1 expression is predictive of gemcitabine outcome in pancreatic cancer: a systematic review. World J. Gastroenterol. 20 (2014), 8482–8490.
133. Norquist, B., Wurz, K.A., Pennil, C.C., Garcia, R., Gross, J., Sakai, W., Karlan, B.Y., Taniguchi, T., Swisher, E.M., Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol. 29 (2011), 3008–3015.
134. Ohno, T., Hiraga, J., Ohashi, H., Sugisaki, C., Li, E., Asano, H., Ito, T., Nagai, H., Yamashita, Y., Mori, N., Kinoshita, T., Naoe, T., Loss of O6-methylguanine-DNA methyltransferase protein expression is a favorable prognostic marker in diffuse large B-cell lymphoma. Int. J. Hematol. 83 (2006), 341–347.
135. Organista-Nava, J., Gomez-Gomez, Y., Saavedra-Herrera, M.V., Rivera-Ramirez, A.B., Teran-Porcayo, M.A., Alarcon-Romero Ldel, C., Illades-Aguiar, B., Leyva-Vazquez, M.A., Polymorphisms of the gamma-glutamyl hydrolase gene and risk of relapse to acute lymphoblastic leukemia in Mexico. Leukem. Res. 34 (2010), 728–732.
136. Pang, B., de Jong, J., Qiao, X., Wessels, L.F., Neefjes, J., Chemical profiling of the genome with anti-cancer drugs defines target specificities. Nat. Chem. Biol. 11 (2015), 472–480.
137. Pang, B., Qiao, X., Janssen, L., Velds, A., Groothuis, T., Kerkhoven, R., Nieuwland, M., Ovaa, H., Rottenberg, S., van Tellingen, O., Janssen, J., Huijgens, P., Zwart, W., Neefjes, J., Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin. Nat. Commun., 4, 2013, p1908.
138. Park, S.Y., Lam, W., Cheng, Y.C., X-ray repair cross-complementing gene I protein plays an important role in camptothecin resistance. Cancer Res. 62 (2002), 459–465.
139. Pastor-Anglada, M., Perez-Torras, S., Nucleoside transporter proteins as biomarkers of drug responsiveness and drug targets. Front. Pharmacol., 6, 2015, p13.
140. Patankar, N.A., Pritchard, J., van Grinsven, M., Osooly, M., Bally, M.B., Topotecan and doxorubicin combination to treat recurrent ovarian cancer: the influence of drug exposure time and delivery systems to achieve optimum therapeutic activity. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 19 (2013), 865–877.
141. Patutina, O.A., Mironova, N.L., Popova, N.A., Kaledin, V.I., Nikolin, V.P., Vlassov, V.V., Zenkova, M.A., The siRNA targeted to mdr1b and mdr1a mRNAs in vivo sensitizes murine lymphosarcoma to chemotherapy. BMC Cancer, 10, 2010, p204.
142. Pirker, R., Pereira, J.R., von Pawel, J., Krzakowski, M., Ramlau, R., Park, K., de Marinis, F., Eberhardt, W.E., Paz-Ares, L., Storkel, S., Schumacher, K.M., von Heydebreck, A., Celik, I., O'Byrne, K.J., EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol. 13 (2012), 33–42.
143. Planells-Cases, R., Lutter, D., Guyader, C., Gerhards, N.M., Ullrich, F., Elger, D.A., Kucukosmanoglu, A., Xu, G., Voss, F.K., Reincke, S.M., Stauber, T., Blomen, V.A., Vis, D.J., Wessels, L.F., Brummelkamp, T.R., Borst, P., Rottenberg, S., Jentsch, T.J., Subunit composition of VRAC channels determines substrate specificity and cellular resistance to Pt-based anti-cancer drugs. EMBO J. 34 (2015), 2993–3008.
144. Pommier, Y., Drugging topoisomerases: lessons and challenges. ACS Chem. Biol. 8:1 (2013), 82–95.
145. Pommier, Y., Pourquier, P., Urasaki, Y., Wu, J., Laco, G.S., Topoisomerase I inhibitors: selectivity and cellular resistance. Drug Resist Updat 2:5 (1999), 307–318.
146. Pritchard, J.R., Lauffenburger, D.A., Hemann, M.T., Understanding resistance to combination chemotherapy. Drug Resist. Updates: Rev. Comment. Antimicrob. Anticancer Chemother. 15 (2012), 249–257.
147. Qiu, A., Jansen, M., Sakaris, A., Min, S.H., Chattopadhyay, S., Tsai, E., Sandoval, C., Zhao, R., Akabas, M.H., Goldman, I.D., Identification of an intestinal folate transporter and the molecular basis for hereditary folate malabsorption. Cell 127 (2006), 917–928.
148. Raz, S., Stark, M., Assaraf, Y.G., Binding of a Smad4/Ets-1 complex to a novel intragenic regulatory element in exon12 of FPGS underlies decreased gene expression and antifolate resistance in leukemia. Oncotarget 5 (2014), 9183–9198.
149. Raz, S., Stark, M., Assaraf, Y.G., Folylpoly-γ-glutamate synthetase: a key determinant of folate homeostasis and antifolate resistance in cancer. Drug Resist. Updates, 2016.
150. Rebucci, M., Michiels, C., Molecular aspects of cancer cell resistance to chemotherapy. Biochem. Pharmacol. 85 (2013), 1219–1226.
151. Regev, R., Eytan, G.D., Flip-flop of doxorubicin across erythrocyte and lipid membranes. Biochem. Pharmacol. 54 (1997), 1151–1158.
152. Regev, R., Yeheskely-Hayon, D., Katzir, H., Eytan, G.D., Transport of anthracyclines and mitoxantrone across membranes by a flip-flop mechanism. Biochem. Pharmacol. 70 (2005), 161–169.
153. Rothem, L., Ifergan, I., Kaufman, Y., Priest, D.G., Jansen, G., Assaraf, Y.G., Resistance to multiple novel antifolates is mediated via defective drug transport resulting from clustered mutations in the reduced folate carrier gene in human leukaemia cell lines. Biochem. J. 367 (2002), 741–750.
154. Rots, M.G., Pieters, R., Peters, G.J., Noordhuis, P., van Zantwijk, C.H., Kaspers, G.J., Hahlen, K., Creutzig, U., Veerman, A.J., Jansen, G., Role of folylpolyglutamate synthetase and folylpolyglutamate hydrolase in methotrexate accumulation and polyglutamylation in childhood leukemia. Blood 93 (1999), 1677–1683.
155. Rouzier, R., Rajan, R., Wagner, P., Hess, K.R., Gold, D.L., Stec, J., …, Pusztai, L., Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. Proc Natl Acad Sci U S A 102:23 (2005), 8315–8320.
156. Sakai, W., Swisher, E.M., Karlan, B.Y., Agarwal, M.K., Higgins, J., Friedman, C., Villegas, E., Jacquemont, C., Farrugia, D.J., Couch, F.J., Urban, N., Taniguchi, T., Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 451 (2008), 1116–1120.
157. Salonga, D., Danenberg, K.D., Johnson, M., Metzger, R., Groshen, S., Tsao-Wei, D.D., Lenz, H.J., Leichman, C.G., Leichman, L., Diasio, R.B., Danenberg, P.V., Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 6 (2000), 1322–1327.
158. Sawant, A., Kothandapani, A., Zhitkovich, A., Sobol, R.W., Patrick, S.M., Role of mismatch repair proteins in the processing of cisplatin interstrand cross-links. DNA Rep. 35 (2015), 126–136.
159. Schellens, J.H., Maliepaard, M., Scheper, R.J., Scheffer, G.L., Jonker, J.W., Smit, J.W., …, Schinkel, A.H., Transport of topoisomerase I inhibitors by the breast cancer resistance protein potential clinical implications. Ann. N Y Acad. Sci. 922 (2000), 188–194.
160. Schramm, A., De Gregorio, N., Widschwendter, P., Fink, V., Huober, J., Targeted Therapies in HER2-Positive Breast Cancer - a Systematic Review. Breast Care (Basel) 10:3 (2015), 173–178.
161. Schumacher, T.N., Schreiber, R.D., Neoantigens in cancer immunotherapy. Science (New York, NY) 348 (2015), 69–74.
162. Serdjebi, C., Milano, G., Ciccolini, J., Role of cytidine deaminase in toxicity and efficacy of nucleosidic analogs. Expert Opin. Drug Metab. Toxicol. 11 (2015), 665–672.
163. Shapira, A., Livney, Y.D., Broxterman, H.J., Assaraf, Y.G., Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance. Drug Resist. Updates: Rev. Comment. Antimicrob. Anticancer Chemother. 14 (2011), 150–163.
164. Sharma, S.V., Lee, D.Y., Li, B., Quinlan, M.P., Takahashi, F., Maheswaran, S., McDermott, U., Azizian, N., Zou, L., Fischbach, M.A., Wong, K.K., Brandstetter, K., Wittner, B., Ramaswamy, S., Classon, M., Settleman, J., A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141 (2010), 69–80.
165. Siddik, Z.H., Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22 (2003), 7265–7279.
166. Sinnott, R., Winters, L., Larson, B., Mytsa, D., Taus, P., Cappell, K.M., Whitehurst, A.W., Mechanisms promoting escape from mitotic stress-induced tumor cell death. Cancer Res. 74:14 (2014), 3857–3869.
167. Sladek, N.E., Kollander, R., Sreerama, L., Kiang, D.T., Cellular levels of aldehyde dehydrogenases (ALDH1A1 and ALDH3A1) as predictors of therapeutic responses to cyclophosphamide-based chemotherapy of breast cancer: a retrospective study. Rational individualization of oxazaphosphorine-based cancer chemotherapeutic regimens. Cancer Chemother. Pharmacol. 49 (2002), 309–321.
168. Slamon, D.J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., Baselga, J., Norton, L., Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344 (2001), 783–792.
169. Smith, C.C., Wang, Q., Chin, C.S., Salerno, S., Damon, L.E., Levis, M.J., Perl, A.E., Travers, K.J., Wang, S., Hunt, J.P., Zarrinkar, P.P., Schadt, E.E., Kasarskis, A., Kuriyan, J., Shah, N.P., Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature 485 (2012), 260–263.
170. Smoter, M., Bodnar, L., Grala, B., Stec, R., Zieniuk, K., Kozlowski, W., Szczylik, C., Tau protein as a potential predictive marker in epithelial ovarian cancer patients treated with paclitaxel/platinum first-line chemotherapy. J. Exp. Clin. Cancer Res., 32, 2013, 25.
171. Souers, A.J., Leverson, J.D., Boghaert, E.R., Ackler, S.L., Catron, N.D., Chen, J., Dayton, B.D., Ding, H., Enschede, S.H., Fairbrother, W.J., Huang, D.C., Hymowitz, S.G., Jin, S., Khaw, S.L., Kovar, P.J., Lam, L.T., Lee, J., Maecker, H.L., Marsh, K.C., Mason, K.D., Mitten, M.J., Nimmer, P.M., Oleksijew, A., Park, C.H., Park, C.M., Phillips, D.C., Roberts, A.W., Sampath, D., Seymour, J.F., Smith, M.L., Sullivan, G.M., Tahir, S.K., Tse, C., Wendt, M.D., Xiao, Y., Xue, J.C., Zhang, H., Humerickhouse, R.A., Rosenberg, S.H., Elmore, S.W., ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat. Med. 19 (2013), 202–208.
172. Spratlin, J., Sangha, R., Glubrecht, D., Dabbagh, L., Young, J.D., Dumontet, C., Cass, C., Lai, R., Mackey, J.R., The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 10 (2004), 6956–6961.
173. Stark, M., Rothem, L., Jansen, G., Scheffer, G.L., Goldman, I.D., Assaraf, Y.G., Antifolate resistance associated with loss of MRP1 expression and function in Chinese hamster ovary cells with markedly impaired export of folate and cholate. Mol. Pharmacol. 64 (2003), 220–227.
174. Stewart, L., Redinbo, M.R., Qiu, X., Hol, W.G., Champoux, J.J., A model for the mechanism of human topoisomerase I. Science 279:5356 (1998), 1534–1541.
175. Sudo, T., Nitta, M., Saya, H., Ueno, N.T., Dependence of paclitaxel sensitivity on a functional spindle assembly checkpoint. Cancer Res. 64:7 (2004), 2502–2508.
176. Szakacs, G., Paterson, J.K., Ludwig, J.A., Booth-Genthe, C., Gottesman, M.M., Targeting multidrug resistance in cancer. Nat. Rev. Drug Discov. 5 (2006), 219–234.
177. Taddia, L., D'Arca, D., Ferrari, S., Marraccini, C., Severi, L., Ponterini, G., Assaraf, Y.G., Marverti, G., Costi, M.P., Inside the biochemical pathways of thymidylate synthase perturbed by anticancer drugs: novel strategies to overcome cancer chemoresistance. Drug Resist. Updates: Rev. Comment. Antimicrob. Anticancer Chemother. 23 (2015), 20–54.
178. Tang, S.W., Bilke, S., Cao, L., Murai, J., Sousa, F.G., Yamade, M., Rajapakse, V., Varma, S., Helman, L.J., Khan, J., Meltzer, P.S., Pommier, Y., SLFN11 Is a transcriptional target of EWS-FLI1 and a determinant of drug response in Ewing sarcoma. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 21 (2015), 4184–4193.
179. Tiwari, A.K., Zhang, R., Gallo, J.M., Overlapping functions of ABC transporters in topotecan disposition as determined in gene knockout mouse models. Mol. Cancer Ther. 12:7 (2013), 1343–1355.
180. Undevia, S.D., Gomez-Abuin, G., Ratain, M.J., Pharmacokinetic variability of anticancer agents. Nat. Rev. Cancer 5 (2005), 447–458.
181. Van Allen, E.M., Mouw, K.W., Kim, P., Iyer, G., Wagle, N., Al-Ahmadie, H., Zhu, C., Ostrovnaya, I., Kryukov, G.V., O'Connor, K.W., Sfakianos, J., Garcia-Grossman, I., Kim, J., Guancial, E.A., Bambury, R., Bahl, S., Gupta, N., Farlow, D., Qu, A., Signoretti, S., Barletta, J.A., Reuter, V., Boehm, J., Lawrence, M., Getz, G., Kantoff, P., Bochner, B.H., Choueiri, T.K., Bajorin, D.F., Solit, D.B., Gabriel, S., D'Andrea, A., Garraway, L.A., Rosenberg, J.E., Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Cancer Discov. 4 (2014), 1140–1153.
182. van der Wilt, C.L., Backus, H.H., Smid, K., Comijn, L., Veerman, G., Wouters, D., Voorn, D.A., Priest, D.G., Bunni, M.A., Mitchell, F., Jackman, A.L., Jansen, G., Peters, G.J., Modulation of both endogenous folates and thymidine enhance the therapeutic efficacy of thymidylate synthase inhibitors. Cancer Res. 61 (2001), 3675–3681.
183. van Vuuren, R.J., Visagie, M.H., Theron, A.E., Joubert, A.M., Antimitotic drugs in the treatment of cancer. Cancer Chemother. Pharmacol. 76:6 (2015), 1101–1112.
184. Vecchione, L., Gambino, V., Raaijmakers, J., Schlicker, A., Fumagalli, A., Russo, M., Villanueva, A., Beerling, E., Bartolini, A., Mollevi, D.G., El-Murr, N., Chiron, M., Calvet, L., Nicolazzi, C., Combeau, C., Henry, C., Simon, I.M., Tian, S., In't Veld, S., D'Ario, G., Mainardi, S., Beijersbergen, R.L., Lieftink, C., Linn, S., Rumpf-Kienzl, C., Delorenzi, M., Wessels, L., Salazar, R., Di Nicolantonio, F., Bardelli, A., van Rheenen, J., Medema, R.H., Tejpar, S., Bernards, R., A vulnerability of a subset of colon cancers with potential clinical utility. Cell 165 (2016), 317–330.
185. Viaud, S., Saccheri, F., Mignot, G., Yamazaki, T., Daillere, R., Hannani, D., Enot, D.P., Pfirschke, C., Engblom, C., Pittet, M.J., Schlitzer, A., Ginhoux, F., Apetoh, L., Chachaty, E., Woerther, P.L., Eberl, G., Berard, M., Ecobichon, C., Clermont, D., Bizet, C., Gaboriau-Routhiau, V., Cerf-Bensussan, N., Opolon, P., Yessaad, N., Vivier, E., Ryffel, B., Elson, C.O., Dore, J., Kroemer, G., Lepage, P., Boneca, I.G., Ghiringhelli, F., Zitvogel, L., The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science (New York, NY) 342 (2013), 971–976.
186. Vidal, S.J., Rodriguez-Bravo, V., Galsky, M., Cordon-Cardo, C., Domingo-Domenech, J., Targeting cancer stem cells to suppress acquired chemotherapy resistance. Oncogene 33 (2014), 4451–4463.
187. Vogler, M., Targeting BCL2-proteins for the treatment of solid tumours. Adv. Med., 2014, 2014, p943648.
188. Wang, J.C., Cellular roles of DNA topoisomerases: a molecular perspective. Nat. Rev. Mol. Cell Biol. 3:6 (2002), 430–440.
189. Wang, L.E., Yin, M., Dong, Q., Stewart, D.J., Merriman, K.W., Amos, C.I., Spitz, M.R., Wei, Q., DNA repair capacity in peripheral lymphocytes predicts survival of patients with non-small-cell lung cancer treated with first-line platinum-based chemotherapy. J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol. 29 (2011), 4121–4128.
190. Wang, Y., Chen, J., Li, X., He, Y., Hu, B., Ji, C., Xu, J., Genetic polymorphisms of ERCC1 and their effects on the efficacy of cisplatin-based chemotherapy in advanced esophageal carcinoma. Oncol. Rep. 25 (2011), 1047–1052.
191. Waters, C.E., Saldivar, J.C., Hosseini, S.A., Huebner, K., The FHIT gene product: tumor suppressor and genome “caretaker”. Cell. Mol. Life Sci.: CMLS 71 (2014), 4577–4587.
192. Wee, Z.N., Yatim, S.M., Kohlbauer, V.K., Feng, M., Goh, J.Y., Yi, B., …, Yu, Q., IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel. Nat. Commun., 6, 2015, 8746.
193. Weeks, L.D., Fu, P., Gerson, S.L., Uracil-DNA glycosylase expression determines human lung cancer cell sensitivity to pemetrexed. Mol. Cancer Therapeut. 12 (2013), 2248–2260.
194. Wei, C.H., Gorgan, T.R., Elashoff, D.A., Hines, O.J., Farrell, J.J., Donahue, T.R., A meta-analysis of gemcitabine biomarkers in patients with pancreaticobiliary cancers. Pancreas 42 (2013), 1303–1310.
195. Wei, G., Ni, W., Chiao, J.W., Cai, Z., Huang, H., Liu, D., A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome. J. Hematol. Oncol., 4, 2011, 46.
196. Weiss, R.B., The anthracyclines: will we ever find a better doxorubicin?. Semin. Oncol. 19 (1992), 670–686.
197. Werner, H.M., Trovik, J., Halle, M.K., Wik, E., Akslen, L.A., Birkeland, E., …, Salvesen, H.B., Stathmin protein level, a potential predictive marker for taxane treatment response in endometrial cancer. PLoS One, 9(2), 2014, e90141.
198. Whitehead, V.M., Rosenblatt, D.S., Vuchich, M.J., Shuster, J.J., Witte, A., Beaulieu, D., Accumulation of methotrexate and methotrexate polyglutamates in lymphoblasts at diagnosis of childhood acute lymphoblastic leukemia: a pilot prognostic factor analysis. Blood 76 (1990), 44–49.
199. Wijdeven, R.H., Pang, B., van der Zanden, S.Y., Qiao, X., Blomen, V., Hoogstraat, M., Lips, E.H., Janssen, L., Wessels, L., Brummelkamp, T.R., Neefjes, J., Genome-wide identification and characterization of novel factors conferring resistance to topoisomerase II poisons in cancer. Cancer Res. 75 (2015), 4176–4187.
200. Wilson, P.M., Danenberg, P.V., Johnston, P.G., Lenz, H.J., Ladner, R.D., Standing the test of time: targeting thymidylate biosynthesis in cancer therapy. Nat. Rev. Clin. Oncol. 11 (2014), 282–298.
201. Wilson, P.M., LaBonte, M.J., Lenz, H.J., Mack, P.C., Ladner, R.D., Inhibition of dUTPase induces synthetic lethality with thymidylate synthase-targeted therapies in non-small cell lung cancer. Mol. Cancer Therapeut. 11 (2012), 616–628.
202. Wojtuszkiewicz, A., Peters, G.J., van Woerden, N.L., Dubbelman, B., Escherich, G., Schmiegelow, K., Sonneveld, E., Pieters, R., van de Ven, P.M., Jansen, G., Assaraf, Y.G., Kaspers, G.J., Cloos, J., Methotrexate resistance in relation to treatment outcome in childhood acute lymphoblastic leukemia. J. Hematol. Oncol., 8, 2015, p61.
203. Wojtuszkiewicz, A., Raz, S., Stark, M., Assaraf, Y.G., Jansen, G., Peters, G.J., Sonneveld, E., Kaspers, G.J., Cloos, J., Folylpolyglutamate synthetase splicing alterations in acute lymphoblastic leukemia are provoked by methotrexate and other chemotherapeutics and mediate chemoresistance. Int. J. Cancer. J. Int. Cancer 138 (2016), 1645–1656.
204. Wu, D.W., Lee, M.C., Hsu, N.Y., Wu, T.C., Wu, J.Y., Wang, Y.C., Cheng, Y.W., Chen, C.Y., Lee, H., FHIT loss confers cisplatin resistance in lung cancer via the AKT/NF-kappaB/Slug-mediated PUMA reduction. Oncogene 34 (2015), 2505–2515.
205. Xu, H., Dephoure, N., Sun, H., Zhang, H., Fan, F., Liu, J., …, Zhou, C., Proteomic profiling of paclitaxel treated cells identifies a novel mechanism of drug resistance mediated by PDCD4. J. Proteome. Res. 14:6 (2015), 2480–2491.
206. Xu, Y., Her, C., Inhibition of topoisomerase (DNA) I (TOP1): DNA damage repair and anticancer therapy. Biomolecules 5 (2015), 1652–1670.
207. Yang, D., Chen, M.B., Wang, L.Q., Yang, L., Liu, C.Y., Lu, P.H., Bcl-2 expression predicts sensitivity to chemotherapy in breast cancer: a systematic review and meta-analysis. J. Exp. Clin. Cancer Res.: CR, 32, 2013, 105.
208. Yang, F., Kemp, C.J., Henikoff, S., Doxorubicin enhances nucleosome turnover around promoters. Curr. Biol.: CB 23 (2013), 782–787.
209. Yatim, N., Jusforgues-Saklani, H., Orozco, S., Schulz, O., Barreira da Silva, R., Reis e Sousa, C., Green, D.R., Oberst, A., Albert, M.L., RIPK1 and NF-kappaB signaling in dying cells determines cross-priming of CD8(+) T cells. Science (New York, NY) 350 (2015), 328–334.
210. Yin, S., Bhattacharya, R., Cabral, F., Human mutations that confer paclitaxel resistance. Mol. Cancer Ther. 9:2 (2010), 327–335.
211. Yu, Y., Gaillard, S., Phillip, J.M., Huang, T.C., Pinto, S.M., Tessarollo, N.G., …, Shih Ie, M., Inhibition of spleen tyrosine kinase potentiates paclitaxel-induced cytotoxicity in ovarian cancer cells by stabilizing microtubules. Cancer Cell 28:1 (2015), 82–96.
212. Zaffaroni, N., Pennati, M., Colella, G., Perego, P., Supino, R., Gatti, L., …, Daidone, M.G., Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer. Cell Mol. Life Sci. 59:8 (2002), 1406–1412.
213. Zarrinkar, P.P., Gunawardane, R.N., Cramer, M.D., Gardner, M.F., Brigham, D., Belli, B., Karaman, M.W., Pratz, K.W., Pallares, G., Chao, Q., Sprankle, K.G., Patel, H.K., Levis, M., Armstrong, R.C., James, J., Bhagwat, S.S., AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Blood 114 (2009), 2984–2992.
214. Zhang, J., Tian, Q., Chan, S.Y., Duan, W., Zhou, S., Insights into oxazaphosphorine resistance and possible approaches to its circumvention. Drug Resist. Updates: Rev. Comment. Antimicrob. Anticancer Chemother. 8 (2005), 271–297.
215. Zhao, F., Siu, M.K., Jiang, L., Tam, K.F., Ngan, H.Y., Le, X.F., …, Cheung, A.N., Overexpression of forkhead box protein M1 (FOXM1) in ovarian cancer correlates with poor patient survival and contributes to paclitaxel resistance. PLoS One, 9(11), 2014, e113478.
216. Zheng, X., Carstens, J.L., Kim, J., Scheible, M., Kaye, J., Sugimoto, H., Wu, C.C., LeBleu, V.S., Kalluri, R., Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature 527 (2015), 525–530.
217. Zhitomirsky, B., Assaraf, Y.G., Lysosomal sequestration of hydrophobic weak base chemotherapeutics triggers lysosomal biogenesis and lysosome-dependent cancer multidrug resistance. Oncotarget 6 (2015), 1143–1156.
218. Zhitomirsky, B., Assaraf, Y.G., Lysosomes as mediators of drug resistance in cancer. Drug Resist. Updates: Rev. Comment. Antimicrob. Anticancer Chemother. 24 (2016), 23–33.
219. Zoppoli, G., Regairaz, M., Leo, E., Reinhold, W.C., Varma, S., Ballestrero, A., Doroshow, J.H., Pommier, Y., Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents. Proc. Natl. Acad. Sci. U. S. A. 109 (2012), 15030–15035.